Potito Rosario S.
- Country
- Italy
- Department
- U.O. Ematologia
Research Overview
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
- Phase 2 Evaluation of Nanatinostat and Valganciclovir in Epstein-Barr Virus-Positive Relapsed/Refractory Lymphomas
- Phase 3 Open-Label Evaluation of Epcoritamab with Rituximab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma
Data & Insights
Has run more than one trial at 101 of 282 partner sites.
Specializations
Lymphoma Research
Specializes in investigating innovative treatments for Diffuse Large B-Cell Lymphoma (DLBCL), with particular emphasis on therapeutic approaches for relapsed and refractory cases.
- B-cell lymphoma therapeutics
- Antibody-drug conjugates
- Immunotherapy combinations
Focuses on advancing treatment options through targeted therapies and immunological approaches in lymphoid malignancies.
Hematologic Oncology
Contributes to the development of novel therapeutic combinations in hematologic malignancies, particularly exploring the integration of targeted agents with established immunotherapies.
- Combination therapy strategies
- Rituximab-based treatments
- Refractory disease management
Explores innovative treatment paradigms for patients with resistant or recurring blood cancers.
Clinical Innovation
Investigates comparative therapeutic approaches in aggressive lymphomas, evaluating the efficacy of newer targeted therapies against conventional treatment standards.
- Treatment resistance mechanisms
- Therapeutic optimization
- Patient response assessment
Examines therapeutic strategies aimed at improving outcomes in challenging hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.